oligodendroglioma

Summary

Summary: A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655)

Top Publications

  1. Noshita N, Mashiyama S, Fukawa O, Asano S, Watanabe M, Tominaga T. Extracranial metastasis of anaplastic oligodendroglioma with 1p19q loss of heterozygosity--case report. Neurol Med Chir (Tokyo). 2010;50:161-4 pubmed
    We report a rare case of anaplastic oligodendroglioma with extracranial metastasis, showing 1p19q co-deletion in both the brain tissue and the metastatic site. A 53-year-old man first presented with a left frontal tumor...
  2. Matthews S, Succar P, Jelinek H, McParland B, Buckland M, McLachlan C. Diagnosis of oligodendroglioma: molecular and classical histological assessment in the twenty-first century. Asia Pac J Clin Oncol. 2012;8:213-6 pubmed publisher
    ..We discuss the current trends, limitations and impact of molecular classification in this mini review. ..
  3. Briançon Marjollet A, Balenci L, Fernandez M, Esteve F, Honnorat J, Farion R, et al. NG2-expressing glial precursor cells are a new potential oligodendroglioma cell initiating population in N-ethyl-N-nitrosourea-induced gliomagenesis. Carcinogenesis. 2010;31:1718-25 pubmed publisher
    ..We showed that early low-grade gliomas have characteristics of oligodendroglioma-like tumors and exclusively contain NG2-expressing slow dividing precursor cells, which express early ..
  4. Molinari C, Iorio P, Medri L, Ballardini M, Guiducci G, Cremonini A, et al. Chromosome 1p and 19q evaluation in low-grade oligodendrogliomas: a descriptive study. Int J Mol Med. 2010;25:145-51 pubmed
  5. Kural C, Pusat S, Sentürk T, Secer H, Izci Y. Extracranial metastases of anaplastic oligodendroglioma. J Clin Neurosci. 2011;18:136-8 pubmed publisher
    ..Extracranial metastasis of an anaplastic oligodendroglioma (ODG) is exceptionally rare...
  6. Holmlund C, Haapasalo H, Yi W, Raheem O, Brannstrom T, Bragge H, et al. Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology. 2009;29:242-7 pubmed publisher
    ..The role of LRIG proteins in oligodendroglioma has not previously been studied...
  7. Wu Y, Liu B, Qu L, Tao H. Extracranial skeletal metastasis in anaplastic oligodendroglioma: case report and review of the literature. J Int Med Res. 2011;39:960-7 pubmed
    A case of anaplastic oligodendroglioma with femoral metastasis is presented in a 37-year old male with a 2-year history of progressive headaches and dizziness associated with a 2-month history of epilepsy and right hemiparesis...
  8. Klysik M, Gavito J, Boman D, Miranda R, Hanbali F, de Las Casas L. Intraoperative imprint cytology of central neurocytoma: The great oligodendroglioma mimicker. Diagn Cytopathol. 2010;38:202-7 pubmed publisher
    ..Their distinction during intraoperative consultations from oligodendroglioma, ependymoma (mainly clear cell ependymoma), and non-Hodgkin lymphoma can be a diagnostic challenge...
  9. Ducray F, Idbaih A, Wang X, Cheneau C, Labussiere M, Sanson M. Predictive and prognostic factors for gliomas. Expert Rev Anticancer Ther. 2011;11:781-9 pubmed publisher
    ..Recently, integrated genomic, transcriptomic and epigenetic studies have unraveled new glioblastoma subgroups that further refines the molecular classification of these tumors. Such an approach should be extended to lower grade gliomas. ..

More Information

Publications80

  1. Cordiano V, Miserocchi F, Storti M. Bone marrow metastases from anaplastic oligodendroglioma presenting with pancytopenia and hypogammaglobulinemia: a case report. Tumori. 2011;97:808-11 pubmed publisher
    ..occurred 57 months after the initial diagnosis and 9 months after completing radiotherapy for an anaplastic oligodendroglioma. Four months before the demonstration of visceral metastases was obtained by bone marrow biopsy, the patient ..
  2. Hegi M, Janzer R, Lambiv W, Gorlia T, Kouwenhoven M, Hartmann C, et al. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol. 2012;123:841-52 pubmed publisher
    ..Morphologic features were systematically recorded for 360 cases with particular focus on the presence of an oligodendroglioma-like component and respective correlations with outcome and relevant molecular markers...
  3. Shukla B, Agarwal S, Suri V, Pathak P, Sharma M, Gupta D, et al. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. Neurol India. 2009;57:559-66 pubmed publisher
    ..6% (5/9) of mixed oligoastrocytomas. There was one case each of pediatric oligodendroglioma and mixed oligoastrocytoma, none of which showed 1p/19q loss...
  4. Yip S, Butterfield Y, Morozova O, Chittaranjan S, Blough M, An J, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 2012;226:7-16 pubmed publisher
    b>Oligodendroglioma is characterized by unique clinical, pathological, and genetic features...
  5. Ferrer Luna R, Mata M, Núñez L, Calvar J, Dasi F, Arias E, et al. Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression. J Neurooncol. 2009;95:343-354 pubmed publisher
    ..and 19q have been shown to be sensitive to chemotherapy, thus making 1p-19q status testing a key aspect in oligodendroglioma diagnosis and prognosis...
  6. Bralten L, Kloosterhof N, Gravendeel L, Sacchetti A, Duijm E, Kros J, et al. Integrated genomic profiling identifies candidate genes implicated in glioma-genesis and a novel LEO1-SLC12A1 fusion gene. Genes Chromosomes Cancer. 2010;49:509-17 pubmed publisher
    ..Our data show that integrated genomic profiling can identify genes involved in tumor initiation, and/or progression and can be used as an approach to identify novel fusion genes. ..
  7. van den Bent M, Gravendeel L, Gorlia T, Kros J, Lapre L, Wesseling P, et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res. 2011;17:7148-55 pubmed publisher
    ..Methylation profiling therefore may help identify AODs and AOAs with improved prognosis. ..
  8. Hirose T, Ishizawa K, Shimada S. Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors. Neuropathology. 2010;30:586-96 pubmed publisher
  9. Scheie D, Meling T, Cvancarova M, Skullerud K, Mørk S, Lote K, et al. Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases. Neuro Oncol. 2011;13:1225-33 pubmed publisher
    ..The study suggests that solitary 19q loss is a negative prognostic variable and that 1p/19q loss is associated with prolonged survival also in oligodendroglial tumors without classic histology. ..
  10. Sahm F, Koelsche C, Meyer J, Pusch S, Lindenberg K, Mueller W, et al. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol. 2012;123:853-60 pubmed publisher
    ..CIC and FUBP1 mutations exclusively occurred in presence of either IDH1 or IDH2 mutations. Our data confirm CIC and FUBP1 mutations in oligodendrogliomas and demonstrate the presence of these mutations in oligoastrocytomas...
  11. Klink B, Miletic H, Stieber D, Huszthy P, Campos Valenzuela J, Valenzuela J, et al. A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1. PLoS ONE. 2013;8:e59773 pubmed publisher
    b>Oligodendroglioma poses a biological conundrum for malignant adult human gliomas: it is a tumor type that is universally incurable for patients, and yet, only a few of the human tumors have been established as cell populations in vitro ..
  12. Wang Y, Li S, Chen L, You G, Bao Z, Yan W, et al. Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol. 2012;14:518-25 pubmed publisher
    Glioblastomas (GBMs) containing foci that resemble oligodendroglioma are de?ned as GBM with oligodendroglioma component (GBMO)...
  13. Nielsen M, Christensen H, Kosteljanetz M, Johansen C. Incidence of and survival from oligodendroglioma in Denmark, 1943-2002. Neuro Oncol. 2009;11:311-7 pubmed publisher
    We established the nationwide, population-based incidence of oligodendroglioma in Denmark during 59 years of monitoring and compared the overall survival of patients with oligodendroglial tumors during the periods 1943-1977 and 1978-2002...
  14. Temel S, Kahveci Z. Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma. J Mol Histol. 2009;40:369-77 pubmed publisher
    ..or LCA-MAC (microglia-macrophage) in archival formalin-fixed, paraffin embedded human tissue diagnosed as oligodendroglioma and/or astrocytoma...
  15. Can B, Akpolat I, Meydan D, Uner A, Kandemir B, Soylemezoglu F. Fine-needle aspiration cytology of metastatic oligodendroglioma: case report and literature review. Acta Cytol. 2012;56:97-103 pubmed publisher
    ..Therefore, comprehensive knowledge of diagnostic cytomorphologic findings is required in these cases...
  16. Idbaih A, Dalmasso C, Kouwenhoven M, Jeuken J, Carpentier C, Gorlia T, et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. J Neurooncol. 2011;103:221-30 pubmed publisher
    ..loss of prognostic BACs located on 1p tightly associated with 19q deletion, (2) a longer survival, (3) an oligodendroglioma phenotype, and (4) a frontal location in brain. Type III AOTs (11...
  17. Parkinson J, Afaghi V, Payne C, Buckland M, Brewer J, Biggs M, et al. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre. J Clin Neurosci. 2011;18:329-33 pubmed publisher
    ..We reviewed 105 patients with oligodendroglioma treated at a single centre over 20 years...
  18. Le Mercier M, Fortin S, Mathieu V, Roland I, Spiegl Kreinecker S, Haibe Kains B, et al. Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia. 2009;11:485-96 pubmed
    ..As an oligodendroglioma model, we make use of the Hs683 cell line that has been previously extensively characterized at cell biology,..
  19. Kuo L, Kuo K, Lee M, Wei C, Scaravilli F, Tsai J, et al. Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. Int J Cancer. 2009;124:2872-9 pubmed publisher
  20. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood L, Hruban R, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011;333:1453-5 pubmed publisher
    ..These results suggest a critical role for these genes in the biology and pathology of oligodendrocytes. ..
  21. Appolloni I, Calzolari F, Barilari M, Terrile M, Daga A, Malatesta P. Antagonistic modulation of gliomagenesis by Pax6 and Olig2 in PDGF-induced oligodendroglioma. Int J Cancer. 2012;131:E1078-87 pubmed publisher
    ..as a positive prognostic marker for human gliomas, in a well-characterized in vivo model of PDGF-B-driven oligodendroglioma. In this system, the expression of Pax6 severely impairs tumor propagation by inducing a reduction of cell ..
  22. Reitman Z, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010;102:932-41 pubmed publisher
    ..Study of alterations in these metabolic enzymes may provide insights into the metabolism of cancer cells and uncover novel avenues for development of anticancer therapeutics...
  23. Lass U, Nümann A, von Eckardstein K, Kiwit J, Stockhammer F, Horaczek J, et al. Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event. PLoS ONE. 2012;7:e41298 pubmed publisher
    ..To investigate the dynamics of inter- and intratumoral molecular alterations during tumor progression in recurrent gliomas...
  24. Gravendeel L, Kloosterhof N, Bralten L, van Marion R, Dubbink H, Dinjens W, et al. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat. 2010;31:E1186-99 pubmed publisher
    ..Functional differences between p.R132H and non-p.R132H mutated IDH1 may explain the segregation in distinct glioma subtypes...
  25. Lamoral Theys D, Le Mercier M, Le Calve B, Rynkowski M, Bruyère C, Decaestecker C, et al. Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells. Neoplasia. 2010;12:69-79 pubmed
    ..whereas gliomas with an oligodendroglial origin offer higher sensitivity to chemotherapy, especially when oligodendroglioma cells display 1p19q deletions...
  26. Ray M, Goldstein S, Zhou S, Potamousis K, Sarkar D, Newton M, et al. Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis. BMC Genomics. 2013;14:505 pubmed publisher
    ..In this context, high throughput, single molecule platforms like Optical Mapping offer a unique perspective...
  27. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009;118:599-601 pubmed publisher
    ..This antibody is highly useful for tumor classification, in detecting single infiltrating tumor cells and for the characterization of the cellular role of mutant IDH1 protein...
  28. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174:1149-53 pubmed publisher
  29. Senetta R, Trevisan E, Ruda R, Maldi E, Molinaro L, Lefranc F, et al. Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas. J Neuropathol Exp Neurol. 2009;68:425-31 pubmed publisher
    ..015). These data are the first evidence that cav-1 immunohistochemistry is an independent prognostic marker in tumors with an oligodendroglial component regardless of the 1p/19q status...
  30. Oshiro S, Komatsu F, Tsugu H, Nabeshima K, Abe H, Ohkawa M, et al. [A case of intramedullary cervical metastasis from cerebellar anaplastic oligodendroglioma without typical MR appearance for CSF dissemination]. No Shinkei Geka. 2010;38:279-85 pubmed
    We report a case of intramedullary cervical metastasis from cerebellar anaplastic oligodendroglioma without any MR appearance for CSF dissemination or recurrence in the primary tumor site...
  31. Pytel P, Lukas R. Update on diagnostic practice: tumors of the nervous system. Arch Pathol Lab Med. 2009;133:1062-77 pubmed publisher
    ..Beyond this classification, the practice of diagnostic pathology is also changing with the availability of new tests and the introduction of new treatment options...
  32. Quon H, Hasbini A, Cougnard J, Djafari L, Lacroix C, Abdulkarim B. Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma. J Neurooncol. 2010;96:277-85 pubmed publisher
    ..Also, VEGF over-expression in ODG constitutes an early marker for predicting tumor progression...
  33. Kanamori M, Kumabe T, Sonoda Y, Nishino Y, Watanabe M, Tominaga T. Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors. J Neurooncol. 2009;93:219-28 pubmed publisher
    ..In conclusion, post-progression survival shows significant differences between patients with local and disseminated recurrence. Ki-67 labeling index and nestin expression pattern are useful markers to predict dissemination...
  34. Yang L, Xu X, Liu X, Jin H, Chen Z, Liu X, et al. iTRAQ-based quantitative proteomic analysis for identification of oligodendroglioma biomarkers related with loss of heterozygosity on chromosomal arm 1p. J Proteomics. 2012;77:480-91 pubmed publisher
    The oligodendroglioma (OG) type of glial cell tumors accounts for 2-5% of primary brain neoplasms and 4-15% of gliomas diagnosed worldwide...
  35. Yan H, Parsons D, Jin G, McLendon R, Rasheed B, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-73 pubmed publisher
  36. Lo Cicero A, Schiera G, Proia P, Saladino P, Savettieri G, Di Liegro C, et al. Oligodendroglioma cells shed microvesicles which contain TRAIL as well as molecular chaperones and induce cell death in astrocytes. Int J Oncol. 2011;39:1353-7 pubmed publisher
    Microvesicles (MVs) shed from G26/24 oligodendroglioma cells were previously reported to cause a reproducible, dose-dependent, inhibitory effect on neurite outgrowth, and eventually neuronal apoptosis, when added to primary cultures of ..
  37. Benetkiewicz M, Idbaih A, Cousin P, Boisselier B, Marie Y, Criniere E, et al. NOTCH2 is neither rearranged nor mutated in t(1;19) positive oligodendrogliomas. PLoS ONE. 2009;4:e4107 pubmed publisher
    ..This is the first comprehensive deletion mapping by high density oligo-array of the 1p/19q co-deletion in oligodendroglioma tumors using a methodological approach superior to others previously applied...
  38. Tucker A, Ramsay E, Donnell R. Oligodendroglioma in an african lion (Panthera leo). J Zoo Wildl Med. 2008;39:650-4 pubmed
    ..All findings were consistent with an oligodendroglioma. A second neoplasm, a pulmonary adenoma, was also iidentified at necropsy.
  39. Appin C, Gao J, Chisolm C, Torian M, Alexis D, Vincentelli C, et al. Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics. Brain Pathol. 2013;23:454-61 pubmed publisher
    ..A recently recognized subtype, glioblastoma with oligodendroglioma component (GBM-O), was designated by the World Health Organization (WHO) in 2007...
  40. Lo Cicero A, Majkowska I, Nagase H, Di Liegro I, Troeberg L. Microvesicles shed by oligodendroglioma cells and rheumatoid synovial fibroblasts contain aggrecanase activity. Matrix Biol. 2012;31:229-33 pubmed publisher
    ..We report here that microvesicles shed by oligodendroglioma cells contain an 'aggrecanase' activity, cleaving aggrecan at sites previously identified as targets for ..
  41. Ferrer Luna R, Núñez L, Piquer J, Arias E, Dasi F, Cervio A, et al. Whole-genomic survey of oligodendroglial tumors: correlation between allelic imbalances and gene expression profiles. J Neurooncol. 2011;103:71-85 pubmed publisher
    ..These results allowed us to refine our molecular characterization associated with prognosis, referring exclusively to oligodendroglial tumors...
  42. Snuderl M, Eichler A, Ligon K, Vu Q, Silver M, Betensky R, et al. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res. 2009;15:6430-7 pubmed publisher
    ..The purpose of this study was to evaluate the prognostic significance of polysomy of chromosomes 1 and 19 in the setting of 1p/19q codeletion...
  43. Krijnen J, Fleischeur R, van Berkel M, Westenend P. Metastatic oligodendroglioma: a case report and incidence in The Netherlands. Clin Neuropathol. 2010;29:141-6 pubmed
    b>Oligodendroglioma is a tumor of the central nervous system which rarely metastasizes. The diagnosis of oligodendroglioma is based on histomorphology with limited use of immunohistochemistry...
  44. Klink B, Schlingelhof B, Klink M, Stout Weider K, Patt S, Schrock E. Glioblastomas with oligodendroglial component - common origin of the different histological parts and genetic subclassification. Anal Cell Pathol (Amst). 2010;33:37-54 pubmed publisher
    ..Our objective was to genetically characterize the oligodendroglial and the astrocytic parts of GBMOs and correlate morphologic and genetic features with clinical data...
  45. Ducray F, Criniere E, Idbaih A, Mokhtari K, Marie Y, Paris S, et al. alpha-Internexin expression identifies 1p19q codeleted gliomas. Neurology. 2009;72:156-61 pubmed publisher
    ..alpha-Internexin (INA) is a proneural gene encoding a neurofilament interacting protein that is upregulated in some gliomas, particularly oligodendrogliomas...
  46. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31:337-43 pubmed publisher
    ..Anaplastic oligodendrogliomas, pure (AO) and mixed (anaplastic oligoastrocytoma [AOA]), are chemosensitive, especially if codeleted for 1p/19q, but whether patients live longer after chemoradiotherapy is unknown...
  47. Levidou G, Korkolopoulou P, Agrogiannis G, Paidakakos N, Bouramas D, Patsouris E. Low-grade oligodendroglioma of the pineal gland: a case report and review of the literature. Diagn Pathol. 2010;5:59 pubmed publisher
    ..Gliomas are a very rare subtype of pineal region tumours, whereas oligodendrogliomas of the pineal region are exceedingly rare, since there have been only 3 cases of anaplastic oligodedrogliomas reported this far...
  48. Ciznadija D, Liu Y, Pyonteck S, Holland E, Koff A. Cyclin D1 and cdk4 mediate development of neurologically destructive oligodendroglioma. Cancer Res. 2011;71:6174-83 pubmed publisher
    ..Together, our findings establish that the cyclin D1-cdk4 axis is not only critical in glial tumor cells but also in stromal-derived cells in the surrounding tumor microenvironment that are vital to sustain tumor outgrowth...
  49. Kouwenhoven M, Gorlia T, Kros J, Ibdaih A, Brandes A, Bromberg J, et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol. 2009;11:737-46 pubmed publisher
    ..Tumors with combined 1p and 19q loss (1p(loss)19q(loss)) were histopathologically diagnosed as anaplastic oligodendroglioma, were more frequently located in the frontal lobe, and had a better outcome...
  50. Bromberg J, van den Bent M. Oligodendrogliomas: molecular biology and treatment. Oncologist. 2009;14:155-63 pubmed publisher
    ..The molecular explanation for the greater sensitivity of 1p/19q codeleted tumors is still unclear, and this could, in part, be explained by more frequent MGMT promoter gene methylation...
  51. Fraum T, Barak S, Pack S, Lonser R, Fine H, Quezado M, et al. Spinal cord glioneuronal tumor with neuropil-like islands with 1p/19q deletion in an adult with low-grade cerebral oligodendroglioma. J Neurooncol. 2012;107:421-6 pubmed publisher
    ..concurrent with another CNS tumor; and none of those tested exhibited the 1p/19q deletion typical of oligodendroglioma. A 48-year-old man without significant past medical history was diagnosed with a WHO grade II ..
  52. van den Bent M, Brandes A, Taphoorn M, Kros J, Kouwenhoven M, Delattre J, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31:344-50 pubmed publisher
    Anaplastic oligodendroglioma are chemotherapy-sensitive tumors...
  53. Chamberlain M, Johnston S. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer. 2009;115:1734-43 pubmed publisher
    ..There is no standard therapy for alkylator-resistant AO, and hence a need exists for new therapies...
  54. Kapoor G, Gocke T, Chawla S, Whitmore R, Nabavizadeh A, Krejza J, et al. Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol. 2009;92:373-86 pubmed publisher
    ..Therefore, the combined use of extensive molecular profiling and advanced MR imaging modalities may improve the accuracy of tumor grading, provide prognostic information, and has the potential to influence treatment decisions...
  55. Idbaih A, Ducray F, Dehais C, Courdy C, Carpentier C, de Bernard S, et al. SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. PLoS ONE. 2012;7:e45950 pubmed publisher
    ..Our study showed that the genomic and pathological analyses of AOD are synergistic in detecting relevant clinical and biological subgroups of AOD...
  56. Doucette T, Yang Y, Zhang W, Fuller G, Suki D, Fults D, et al. Bcl-2 promotes malignant progression in a PDGF-B-dependent murine model of oligodendroglioma. Int J Cancer. 2011;129:2093-103 pubmed publisher
    ..We overexpressed Bcl-2 in a PDGFB-dependent mouse model of oligodendroglioma, a common glioma subtype, to assess its effect in vivo...
  57. Persson A, Petritsch C, Swartling F, Itsara M, Sim F, Auvergne R, et al. Non-stem cell origin for oligodendroglioma. Cancer Cell. 2010;18:669-82 pubmed publisher
    ..Using magnetic resonance imaging (MRI) and detailed developmental analyses, we demonstrated that murine oligodendroglioma cells show characteristics of oligodendrocyte progenitor cells (OPCs) and are therapy sensitive, and that ..
  58. Fayeye O, Sankaran V, Sherlala K, Choksey M. Oligodendroglioma presenting with intradural spinal metastases: an unusual cause of cauda equina syndrome. J Clin Neurosci. 2010;17:265-7 pubmed publisher
    We report a 37-year-old man with a primary intracranial oligodendroglioma presenting later with symptomatic multiple cerebrospinal fluid (CSF) intradural drop spinal metastases...
  59. Chen H, Chew L, Packer R, Gallo V. Modulation of the Wnt/beta-catenin pathway in human oligodendroglioma cells by Sox17 regulates proliferation and differentiation. Cancer Lett. 2013;335:361-71 pubmed publisher
    ..We investigated the contribution of these pathways in the proliferation and differentiation of human oligodendroglioma cells (HOG)...
  60. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116:597-602 pubmed publisher
    ..The very high frequency of IDH1 mutations in WHO grade II astrocytic and oligodendroglial gliomas suggests a role in early tumor development...
  61. Favaro R, Appolloni I, Pellegatta S, Sanga A, Pagella P, Gambini E, et al. Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma. Cancer Res. 2014;74:1833-44 pubmed publisher
    ..a conditional genetic deletion mutant in a mouse model of platelet-derived growth factor-induced malignant oligodendroglioma. Transplanting wild-type oligodendroglioma cells into the brain generated lethal tumors, but mice ..
  62. Horbinski C, Nikiforova M, Hobbs J, Bortoluzzi S, Cieply K, Dacic S, et al. The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas. J Neuropathol Exp Neurol. 2012;71:73-82 pubmed publisher
    ..Thus, although PCR-based LOH is a better stratifier of 1p/19q status, FISH still has clinical and prognostic utility, especially if 10q data can be incorporated...
  63. Shaw E, Haylock B, Husband D, Du Plessis D, Sibson D, Warnke P, et al. Gene expression in oligodendroglial tumors. Cell Oncol (Dordr). 2011;34:355-67 pubmed publisher
    ..Oligodendroglial tumors with 1p/19q loss are more likely to be chemosensitive and have longer survival than those with intact 1p/19q, but not all respond to chemotherapy, warranting investigation of the biological basis of chemosensitivity...
  64. Carlsen J, Tietze A, Lassen Y, Rosendal F. Paraplegia due to drop metastases from anaplastic oligodendroglioma. Br J Neurosurg. 2012;26:94-5 pubmed publisher
    In this article, we report on a rare case of spinal seeding from a cerebral anaplastic oligodendroglioma presenting with signs of medullar compression...
  65. Ohgaki H, Kleihues P. Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol. 2011;28:177-83 pubmed publisher
    Low-grade diffuse gliomas WHO grade II (diffuse astrocytoma, oligoastrocytoma, oligodendroglioma) are characterized by frequent IDH1/2 mutations (>80%) that occur at a very early stage...
  66. Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, et al. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol. 2011;121:241-52 pubmed publisher
    ..We conclude that in tumors with an oligodendroglioma-like morphology, binding of H09 is highly specific for oligodendrogliomas or oligoastrocytomas and ..
  67. Cooper L, Gutman D, Long Q, Johnson B, Cholleti S, Kurc T, et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS ONE. 2010;5:e12548 pubmed publisher
    ..65e-4). This gene expression signature was enriched in tumors with oligodendroglioma histology and also predicted improved survival in this tumor type (n =? 43, p ?=? 1.25e-4)...
  68. Kelly J, Blough M, Stechishin O, Chan J, Beauchamp D, Perizzolo M, et al. Oligodendroglioma cell lines containing t(1;19)(q10;p10). Neuro Oncol. 2010;12:745-55 pubmed publisher
    Investigating the biology of oligodendroglioma and its characteristic combined deletion of chromosomal arms 1p and 19q, mediated by an unbalanced translocation, t(1;19)(q10;p10), has been hampered by the lack of cell lines that harbor ..
  69. Cairncross G, Jenkins R. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J. 2008;14:352-7 pubmed publisher
  70. Mikkelsen T, Doyle T, Anderson J, Margolis J, Paleologos N, Gutierrez J, et al. Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol. 2009;92:57-63 pubmed publisher
    The treatment of patients with anaplastic oligodendroglioma (AO) has been significantly impacted by the molecular detection of loss of sequences on chromosomes 1p and 19q...
  71. Iwadate Y, Matsutani T, Shinozaki N, Saeki N. Anaplastic oligodendroglial tumors harboring 1p/19q deletion can be successfully treated without radiotherapy. Anticancer Res. 2011;31:4475-9 pubmed
    ..The excellent treatment results warrant a large-scale clinical study to confirm the efficacy of upfront chemotherapy omitting radiotherapy as initial therapy for anaplastic oligodendroglial tumors with 1p/19q deletion...